Table 1.
Therapeutic mAbs used for inhibition of autoimmune reactivity
| Antibody | Type | Target | Medical uses |
|---|---|---|---|
| Adalimumab | Human, mAb, IgG1 | TNF‐α | Rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis |
| Alemtuzumab | Humanized, mAb, IgG1 | CD52 | Multiple sclerosis |
| Belimumab | Human, mAb, IgG1 | BAFF | Systemic lupus erythematosus |
| Benralizumab | Humanized, mAb, IgG1 | CD125 | Asthma |
| Brodalumab | Human, mAb, IgG2 | IL‐17 | Plaque psoriasis |
| Canakinumab | Human, mAb, IgG1 | IL‐1 | Cryopyrin‐associated periodic syndrome |
| Certolizumab pegol | Humanized, Fab’, IgG1 | TNF‐α | Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis |
| Golimumab | Human, mAb, IgG1 | TNF‐α | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis |
| Guselkumab | Human, mAb, IgG1 | IL23 | Psoriasis |
| Infliximab | Chimeric, mAb, IgG1 | TNF‐α | Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis |
| Itolizumab | Humanized, mAb, IgG1 | CD6 | Psoriasis |
| Ixekizumab | Humanized, mAb, IgG4 | IL‐17A | Plaque psoriasis |
| Mepolizumab | Humanized, mAb, IgG1 | IL‐5 | Asthma and white blood cell diseases |
| Natalizumab | Humanized, mAb, IgG4 | Integrin α 4 | Multiple sclerosis, Crohn's disease |
| Ocrelizumab | Humanized, mAb, IgG1 | CD20 | Rheumatoid arthritis, lupus erythematosus |
| Omalizumab | Humanized, mAb, IgG1 | IgE Fc region | Allergic asthma |
| Reslizumab | Humanized, mAb, IgG4 | IL‐5 | Inflammations of the airways, skin and gastrointestinal tract |
| Risankizumab | Humanized, mAb, IgG1 | IL23A | Crohn's disease, psoriasis, psoriatic arthritis, asthma |
| Rituximab | Chimeric, mAb, IgG1 | CD20 | Rheumatoid arthritis |
| Ruplizumab | Humanized, mAb, IgG1 | CD154 | Rheumatic diseases |
| Sarilumab | Human, mAb, IgG1 | IL6 | Rheumatoid arthritis, ankylosing spondylitis |
| Secukinumab | Human, mAb, IgG1 | IL17A | Uveitis, rheumatoid arthritis, psoriasis |
| Tildrakizumab | Humanized, mAb, IgG1 | IL23 | Immunologically mediated inflammatory disorders |
| Tocilizumab | Humanized, mAb, IgG1 | IL‐6 receptor | Rheumatoid arthritis |
| Ustekinumab | Human, mAb, IgG1 | IL‐12, IL‐23 | Multiple sclerosis, psoriasis, psoriatic arthritis |
| Vedolizumab | Humanized, mAb, IgG1 | Integrin α4β7 | Crohn's disease, ulcerative colitis |